Oncology · Phase 2-3 · pulled 2026-11-06

Multiple myeloma: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of multiple myeloma (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Multiple myeloma: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Dana Farber Cancer Institute Boston, United States · 3 spellings merged	26 20 completed, 6 terminated	NCT03301220 NCT03601078 NCT02441686 6 trials with titles NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT02441686 Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma completed 2025-10-01 NCT05172596 PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma terminated 2025-05-21 Stop reason on the record: “The study was terminated since the sponsor made the decision to discontinue further development of the study drug durcabtagene autoleucel (PHE885).” NCT02916771 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma completed 2025-01-08 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31	2026-05-04	19 NCT04133636 NCT05535244 NCT07258511 NCT07284758	92
2	Hackensack University Medical Center Hackensack, United States · 13 spellings merged	24 15 completed, 9 terminated	NCT04649359 NCT03601078 NCT05561751 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT05561751 Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant completed 2025-10-31 NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies terminated 2025-07-31 Stop reason on the record: “The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.” NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications completed 2024-12-23	2026-08-25	15 NCT04133636 NCT06208150 NCT04181827 NCT06356571	90
3	Medical College of Wisconsin Milwaukee, United States · 13 spellings merged	24 17 completed, 7 terminated	NCT03651128 NCT03601078 NCT03159702 6 trials with titles NCT03651128 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) completed 2026-04-13 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT03159702 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation completed 2025-12-08 NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies terminated 2025-07-31 Stop reason on the record: “The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.” NCT05032820 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma completed 2025-02-20 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-04-13	18 NCT07009899 NCT06208150 NCT04923893 NCT04181827	92
4	Emory University Atlanta, United States · 18 spellings merged	22 16 completed, 6 terminated	NCT04649359 NCT03301220 NCT03601078 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT05172596 PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma terminated 2025-05-21 Stop reason on the record: “The study was terminated since the sponsor made the decision to discontinue further development of the study drug durcabtagene autoleucel (PHE885).” NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons”	2026-08-25	29 NCT07222761 NCT04133636 NCT07266441 NCT05438043	83
5	Memorial Sloan Kettering Cancer Center New York, United States · 14 spellings merged	22 17 completed, 5 terminated	NCT04649359 NCT05014412 NCT05561751 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT05014412 A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment completed 2025-12-12 NCT05561751 Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant completed 2025-10-31 NCT05032820 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma completed 2025-02-20 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT03767257 A Study of Colesevelam for Lenalidomide-Associated Diarrhea completed 2024-11-27	2026-08-25	39 NCT03315026 NCT07222761 NCT07393282 NCT04133636	88
6	Washington University School of Medicine St Louis, United States · 12 spellings merged	22 13 completed, 9 terminated	NCT03301220 NCT03601078 NCT03732703 6 trials with titles NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT05427812 Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma terminated 2024-11-19 Stop reason on the record: “Business decision” NCT04150965 Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT terminated 2024-08-30 Stop reason on the record: “Pharmaceutical support has been discontinued.” NCT02924272 Ixazomib Rollover Study completed 2024-07-03	2026-05-04	20 NCT02253316 NCT07393282 NCT04133636 NCT05438043	90
7	Mayo Clinic in Rochester Rochester, United States · 7 spellings merged	21 16 completed, 5 terminated	NCT03301220 NCT05288062 NCT03941860 6 trials with titles NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT05288062 Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma terminated 2025-07-30 Stop reason on the record: “slow accrual” NCT03941860 Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial completed 2025-01-31 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20 NCT03361748 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma completed 2023-12-20	2026-05-04	30 NCT02253316 NCT07393282 NCT04133636 NCT05535244	90
8	Alexandra General Hospital of Athens Athens, Greece · 17 spellings merged	21 16 completed, 5 terminated	NCT04824794 NCT03180736 NCT03215030 6 trials with titles NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies terminated 2025-07-31 Stop reason on the record: “The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.” NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04191616 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet completed 2024-10-01 NCT02924272 Ixazomib Rollover Study completed 2024-07-03 NCT03439293 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) completed 2023-06-26	2025-07-31	18 NCT07455851 NCT07665450 NCT06208150 NCT07589634	82
9	CHU Nantes Nantes, France · 29 spellings merged	20 16 completed, 4 terminated	NCT03993912 NCT04649359 NCT03301220 6 trials with titles NCT03993912 Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy completed 2026-08-28 NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications completed 2024-12-23 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04191616 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet completed 2024-10-01	2026-08-28	30 NCT05572515 NCT07665450 NCT04133636 NCT05438043	83
10	MD Anderson Cancer Center Houston, United States · 13 spellings merged	19 12 completed, 7 terminated	NCT03901963 NCT03652064 NCT03601078 6 trials with titles NCT03901963 A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant completed 2026-05-04 NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy completed 2026-04-21 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT05561751 Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant completed 2025-10-31 NCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications completed 2024-12-23 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-05-04	25 NCT05828511 NCT05730036 NCT07266441 NCT05455320	90
11	Fakultni nemocnice Brno Brno, Czechia · 10 spellings merged	19 13 completed, 6 terminated	NCT03652064 NCT04824794 NCT03180736 6 trials with titles NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy completed 2026-04-21 NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies terminated 2025-07-31 Stop reason on the record: “The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.” NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT04892446 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma terminated 2024-04-25 Stop reason on the record: “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” NCT03412565 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens completed 2024-04-18 NCT03277105 A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma completed 2024-01-12	2026-04-21	11 NCT05572515 NCT07665450 NCT05438043 NCT05455320	80
12	Hopital Claude Huriez Lille, France · 23 spellings merged	17 11 completed, 6 terminated	NCT03993912 NCT04649359 NCT03652064 6 trials with titles NCT03993912 Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy completed 2026-08-28 NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy completed 2026-04-21 NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies terminated 2025-07-31 Stop reason on the record: “The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.” NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04191616 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet completed 2024-10-01	2026-08-28	21 NCT05828511 NCT05730036 NCT07665450 NCT04133636	78
13	Hosp Clinic de Barcelona Barcelona, Spain · 14 spellings merged	17 13 completed, 4 terminated	NCT04649359 NCT03301220 NCT03180736 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04191616 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet completed 2024-10-01 NCT03412565 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens completed 2024-04-18	2026-08-25	26 NCT05828511 NCT05730036 NCT07149857 NCT05438043	82
14	Universitaetsklinikum Heidelberg Heidelberg, Germany · 15 spellings merged	17 14 completed, 3 terminated	NCT04649359 NCT03301220 NCT05804032 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT05804032 Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma completed 2026-01-30 NCT05675319 Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy terminated 2025-03-21 Stop reason on the record: “The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM stud” NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT03412565 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens completed 2024-04-18	2026-08-25	15 NCT07825064 NCT05572515 NCT05455320 NCT06208150	81
15	Icahn School of Medicine at Mount Sinai New York, United States · 17 spellings merged	17 12 completed, 5 terminated	NCT04052880 NCT03901963 NCT06351644 6 trials with titles NCT04052880 Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM completed 2026-05-27 NCT03901963 A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant completed 2026-05-04 NCT06351644 ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma terminated 2025-04-28 Stop reason on the record: “Study closure is due to insufficient supply of study drug.” NCT05032820 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma completed 2025-02-20 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT04150965 Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT terminated 2024-08-30 Stop reason on the record: “Pharmaceutical support has been discontinued.”	2026-05-27	22 NCT02253316 NCT04133636 NCT05438043 NCT05535244	91
16	Levine Cancer Institute Charlotte, United States · 8 spellings merged	16 13 completed, 3 terminated	NCT03901963 NCT03301220 NCT03652064 6 trials with titles NCT03901963 A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant completed 2026-05-04 NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy completed 2026-04-21 NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT03361306 LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma completed 2025-02-14 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31	2026-05-04	20 NCT05828511 NCT04133636 NCT07149857 NCT07266441	92
17	University of Michigan Ann Arbor, United States · 8 spellings merged	16 11 completed, 5 terminated	NCT03301220 NCT05014412 NCT02969837 6 trials with titles NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT05014412 A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment completed 2025-12-12 NCT02969837 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma completed 2025-12-01 NCT03941860 Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial completed 2025-01-31 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-05-04	14 NCT05438043 NCT05455320 NCT06208150 NCT04634552	92
18	Hospital Universitario de Salamanca Salamanca, Spain · 13 spellings merged	16 11 completed, 5 terminated	NCT04824794 NCT03180736 NCT03215030 6 trials with titles NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies terminated 2025-07-31 Stop reason on the record: “The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.” NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04191616 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet completed 2024-10-01 NCT02924272 Ixazomib Rollover Study completed 2024-07-03 NCT03859427 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma completed 2023-03-31	2025-07-31	14 NCT05828511 NCT07284758 NCT06615479 NCT07901868	78
19	City of Hope Duarte, United States · 8 spellings merged	16 13 completed, 3 terminated	NCT05032820 NCT03732703 NCT05347485 6 trials with titles NCT05032820 Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma completed 2025-02-20 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT05347485 A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma completed 2023-12-15 NCT02633059 Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma completed 2022-11-01 NCT03548207 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma completed 2022-08-23 NCT02509052 Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma completed 2022-06-09	2025-02-20	22 NCT02253316 NCT07266441 NCT04634552 NCT05083169	91
20	Hopital Saint Louis Paris, France · 36 spellings merged	15 11 completed, 4 terminated	NCT04649359 NCT02649790 NCT03215030 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications completed 2024-12-23 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT02541383 A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma completed 2023-09-01 NCT03439293 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) completed 2023-06-26 NCT03859427 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma completed 2023-03-31	2026-08-25	25 NCT05828511 NCT05730036 NCT05572515 NCT07665450	81
21	Policlinico Sant'Orsola Malpighi Bologna, Italy · 21 spellings merged	15 11 completed, 4 terminated	NCT03301220 NCT03180736 NCT03215030 6 trials with titles NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04582539 To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma terminated 2024-08-15 Stop reason on the record: “Strategic Business Decision” NCT03277105 A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma completed 2024-01-12 NCT03361748 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma completed 2023-12-20	2026-05-04	18 NCT05730036 NCT07266441 NCT05455320 NCT05535244	81
22	Hospital Universitari Germans Trias i Pujol Badalona, Spain · 20 spellings merged	14 11 completed, 3 terminated	NCT04649359 NCT03180736 NCT03215030 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03180736 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex completed 2024-11-30 NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma terminated 2024-11-07 Stop reason on the record: “Terminated by the sponsor for strategic reasons” NCT04191616 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet completed 2024-10-01 NCT03412565 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens completed 2024-04-18 NCT03361748 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma completed 2023-12-20	2026-08-25	15 NCT05828511 NCT05730036 NCT05583617 NCT04181827	83
23	Massachusetts General Hospital Boston, United States · 5 spellings merged	14 12 completed, 2 terminated	NCT04649359 NCT05090566 NCT03601078 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT05090566 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma terminated 2026-03-11 Stop reason on the record: “A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests f” NCT03601078 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma completed 2026-01-15 NCT02441686 Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma completed 2025-10-01 NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) completed 2024-12-31 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-08-25	13 NCT07266441 NCT05455320 NCT07284758 NCT04973605	96
24	Nagoya City University Hospital Nagoya, Japan	14 12 completed, 2 terminated	NCT04649359 NCT03301220 NCT03652064 6 trials with titles NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb completed 2026-08-25 NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy completed 2026-04-21 NCT04696809 A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma completed 2026-04-13 NCT05014412 A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment completed 2025-12-12 NCT04649073 Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma terminated 2025-04-09 Stop reason on the record: “This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II.”	2026-08-25	10 NCT06464991 NCT07393282 NCT04923893 NCT05083169	87
25	Vseobecna fakultni nemocnice v Praze Prague, Czechia · 10 spellings merged	14 11 completed, 3 terminated	NCT03301220 NCT03652064 NCT04892446 6 trials with titles NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma completed 2026-05-04 NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy completed 2026-04-21 NCT04892446 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma terminated 2024-04-25 Stop reason on the record: “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” NCT03412565 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens completed 2024-04-18 NCT03277105 A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma completed 2024-01-12 NCT03439293 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) completed 2023-06-26	2026-05-04	10 NCT05572515 NCT07665450 NCT05438043 NCT05455320	82

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Multiple myeloma: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Srinivas Devarakonda Ohio State University Comprehensive Cancer Center	6	NCT04205240 NCT03713294 NCT03477539 NCT02952573 NCT03012880	PMID 42352499 Cancers, 2026 · High match PMID 42004964 Frontiers in immunology, 2026 · High match PMID 41825121 Journal of the National Comprehensive Cancer Network : JNCCN, 2026 · High match
2	Anca Prica Princess Margaret Cancer Centre	5	NCT03959358 NCT03634800 NCT03196947 NCT02356159 NCT02331368	PMID 41536023 European journal of haematology, 2026 · High match PMID 40351553 EJHaem, 2025 · High match PMID 37689547 Clinical lymphoma, myeloma & leukemia, 2023 · High match
3	Alfred Garfall University of Pennsylvannia	3	NCT05032820 NCT02794246 NCT02756728	No paper matched at High or Medium confidence
4	Shaji K Kumar ECOG-ACRIN Cancer Research Group	3	NCT03941860 NCT02880228 NCT02547662	No paper matched at High or Medium confidence
5	Madhav V. Dhodapkar Medical Monitor	3	NCT04150965 NCT03910439 NCT03411031	No paper matched at High or Medium confidence
6	Thomas Lund Odense University Hospital	3	NCT04028115 NCT02780609 NCT02722941	PMID 42581608 British journal of haematology, 2026 · High match PMID 42427930 Clinical hematology international, 2026 · High match PMID 42345737 Hematology reports, 2026 · High match
7	Jeffrey A. Zonder Barbara Ann Karmanos Cancer Institute	3	NCT05028374 NCT04847050 NCT04465760	PMID 42952296 Molecular cancer therapeutics, 2026 · Medium match PMID 42564571 Blood neoplasia, 2026 · High match PMID 42430223 Leukemia & lymphoma, 2026 · High match
8	Thierry Facon University Hospital, Lille	2	NCT03993912 NCT02626481	PMID 42888080 Clinical lymphoma, myeloma & leukemia, 2026 · High match PMID 42864252 Clinical lymphoma, myeloma & leukemia, 2026 · High match PMID 42839070 Leukemia, 2026 · High match
9	Hartmut Goldschmidt GMMG study group	2	NCT05804032 NCT02495922	PMID 42928255 Cancer imaging : the official publication of the International Cancer Imaging Society, 2026 · High match PMID 42839070 Leukemia, 2026 · High match PMID 42637879 Leukemia, 2026 · High match
10	Andrzej Jakubowiak University of Chicago	2	NCT02969837 NCT02389517	PMID 42492029 JCO precision oncology, 2026 · High match PMID 42085642 Blood advances, 2026 · High match PMID 41313549 Advances in therapy, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.